Case reports in ophthalmology · 2023
Isolated Internal Ophthalmoplegia from Posterior Cerebral Artery Neurovascular Conflict.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chronopoulos Argyrios, Consigli Andrea, Heim Julia, Schutz James S, Becker Minerva, Krastel Hermann, Hattenbach Lars-Olof
Аннотация
INTRODUCTION: This study aimed to determine the maximum tolerated dose (MTD) of pegylated liposomal doxorubicin (PLD) combined with both ifosfamide (IFO) and supported by human granulocyte colony-stimulating factor (rhG-CSF) for treating advanced soft tissue sarcoma (STS).
METHODS: Twenty-three patients were enrolled in this trial with 3+3 dose-escalation from January 2020 to September 2022. PLD was initiated at 30 mg/m2 and incrementally escalated by 5 mg/m2 per step. MTD was the primary endpoint, and the safety profile served as the secondary endpoint.
RESULTS: Two patients treated with PLD (55 mg/m2) experienced dose-limiting toxicities. Ultimately, the MTD of PLD was established as 50 mg/m2 (single cycle) in combination of IFO (3 g/m2/day for days 1-3) and supported by rhG-CSF. Across all dose levels, common grade 3/4 adverse events included leukopenia (86.96%), neutropenia (82.61%), and lymphopenia (56.52%). Twelve of the 23 patients voluntarily chose to continue treatment with this regimen. The overall response rate was 33.33% (95% confidence interval: 9.92-65.11), and the disease control rate was 83.33% (95% confidence interval: 51.59-97.91).
CONCLUSION: This study successfully determined the MTD of PLD in combination with IFO and rhG-CSF for advanced STS, offering a potentially valuable treatment option with a tolerable safety profile.
METHODS: Twenty-three patients were enrolled in this trial with 3+3 dose-escalation from January 2020 to September 2022. PLD was initiated at 30 mg/m2 and incrementally escalated by 5 mg/m2 per step. MTD was the primary endpoint, and the safety profile served as the secondary endpoint.
RESULTS: Two patients treated with PLD (55 mg/m2) experienced dose-limiting toxicities. Ultimately, the MTD of PLD was established as 50 mg/m2 (single cycle) in combination of IFO (3 g/m2/day for days 1-3) and supported by rhG-CSF. Across all dose levels, common grade 3/4 adverse events included leukopenia (86.96%), neutropenia (82.61%), and lymphopenia (56.52%). Twelve of the 23 patients voluntarily chose to continue treatment with this regimen. The overall response rate was 33.33% (95% confidence interval: 9.92-65.11), and the disease control rate was 83.33% (95% confidence interval: 51.59-97.91).
CONCLUSION: This study successfully determined the MTD of PLD in combination with IFO and rhG-CSF for advanced STS, offering a potentially valuable treatment option with a tolerable safety profile.